Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of BMS-986278 in pulmonary fibrosis
MOH_2021-02-28_009804Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of admilparant in idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and pulmonary fibrosis (PF) (3 arms), sponsored by Bristol Myers Squibb. Started Jan 2021; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)progressive pulmonary fibrosis (PPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on MOH_2021-02-28_009804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-28_009804.